MannKind Corp. (MNKD) Relaunches Groundbreaking Inhalable Insulin Afrezza®, Promotes New Copay System
With over 29 million Americans living with diabetes, and more than 86 million with prediabetes, this disease is the seventh leading cause of death and swallows approximately 20% of nationwide healthcare spending, according to Centers for Disease Control and Prevention (CDC) statistics (http://nnw.fm/uUEx3). Healthcare officials, patients and doctors alike are always actively searching for new therapies or innovative yet affordable treatments to combat this disease. This is where leading biopharmaceutical company MannKind Corporation (NASDAQ: MNKD) and its groundbreaking inhalable insulin product Afrezza® come in. Touted as the first successful insulin inhaler on the U.S. market, Afrezza is a fast-acting inhalable…